Department of Pediatrics, Juliana Children's Hospital, HAGA Hospital, The Hague, The Netherlands.
Am J Obstet Gynecol. 2012 Mar;206(3):204.e1-5. doi: 10.1016/j.ajog.2011.12.035. Epub 2012 Jan 18.
To evaluate long-term neurodevelopmental outcome of children treated with intrauterine transfusions for fetal anemia because of parvovirus B19 infection.
Children treated with intrauterine transfusions for fetal anemia because of parvovirus B19 infection underwent standardized age-appropriate neurodevelopmental testing. Main outcome was the incidence of neurodevelopmental impairment.
Twenty-eight children were evaluated at a median age of 5 years (range, 1.5-13 years). Neurodevelopmental impairment was diagnosed in 3 of 28 (11%) children, including 1 child with combined cerebral palsy and severe developmental delay and 2 children with isolated severe developmental delay.
Neurodevelopmental impairment in children treated with intrauterine transfusion for parvovirus B19 infection is increased compared with the general population. Large long-term follow-up studies are required to determine potential risk factors.
评估因细小病毒 B19 感染而接受宫内输血治疗胎儿贫血的儿童的长期神经发育结局。
因细小病毒 B19 感染而接受宫内输血治疗胎儿贫血的儿童接受了标准化的适合年龄的神经发育测试。主要结局是神经发育障碍的发生率。
28 名儿童在中位数年龄为 5 岁（范围，1.5-13 岁）时进行了评估。28 名儿童中有 3 名（11%）被诊断为神经发育障碍，包括 1 名合并脑瘫和严重发育迟缓的儿童，以及 2 名单纯严重发育迟缓的儿童。
与一般人群相比，接受宫内输血治疗细小病毒 B19 感染的儿童的神经发育障碍发生率增加。需要进行大型长期随访研究以确定潜在的危险因素。
